drugset / Trial / NCT00934440
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
SequentialOpen-labelTreatment
Summary
To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in patients with advanced renal cell cancer treated with combination of 5-azacitidine and bevacizumab.
Timeline
- Start
- 2009-06
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 35 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 55 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |